2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642 Post author:alarpharm Post published:9 . 5 . 2022 Post category:Media releases You Might Also Like 2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020 2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185). 21 . 4 . 2021 2021/08/25 ALA-1000 Receive notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC), Application No. 2019/00890. 3 . 9 . 2021 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021 2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022
2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020
2021/04/16 ALA-1000 Receive notice of allowance for patent registration from Korean Intellectual Property Office (Application No. 10-2019-7009185). 21 . 4 . 2021
2021/08/25 ALA-1000 Receive notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC), Application No. 2019/00890. 3 . 9 . 2021
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2022/01/13 Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 14 . 1 . 2022
